Skip to Content
Merck

Mitohormesis Primes Tumor Invasion and Metastasis.

Cell reports (2019-05-23)
Timothy C Kenny, Amanda J Craig, Augusto Villanueva, Doris Germain
ABSTRACT

Moderate mitochondrial stress can lead to persistent activation of cytoprotective mechanisms - a phenomenon termed mitohormesis. Here, we show that mitohormesis primes a subpopulation of cancer cells to basally upregulate mitochondrial stress responses, such as the mitochondrial unfolded protein response (UPRmt) providing an adaptive metastatic advantage. In this subpopulation, UPRmt activation persists in the absence of stress, resulting in reduced oxidative stress indicative of mitohormesis. Mechanistically, we showed that the SIRT3 axis of UPRmt is necessary for invasion and metastasis. In breast cancer patients, a 7-gene UPRmt signature demonstrated that UPRmt-HIGH patients have significantly worse clinical outcomes, including metastasis. Transcriptomic analyses revealed that UPRmt-HIGH patients have expression profiles characterized by metastatic programs and the cytoprotective outcomes of mitohormesis. While mitohormesis is associated with health and longevity in non-pathological settings, these results indicate that it is perniciously used by cancer cells to promote tumor progression.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Mn-SOD Antibody, Upstate®, from rabbit
Sigma-Aldrich
Anti-SIRT3 (CT) Antibody, from rabbit
Sigma-Aldrich
Anti-Actin Antibody, clone C4, clone C4, Chemicon®, from mouse
Sigma-Aldrich
Anti-Actin Antibody, clone C4, ascites fluid, clone C4, Chemicon®